0
* Novo set to pay Hengrui up to $2.6 billion for rights to pill * China develops nearly 250 experimental treatments * Hengrui candidate shows potential for once-weekly dosage (Adds investor comment in
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
